ArticleJournal of autism and developmental disorders2025
Harnessing Trial-to-Trial Variability of EEG Spectral Characteristics to Understand Autism.
Article in Journal of autism and developmental disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposesThere is a great need for mechanistically informed biomarkers to understand autism spectrum disorder (ASD) and guide treatment. Electroencephalography (EEG) is a non-invasive method for identifying objective biomarkers, but traditional trial-averaged metrics may mask neural variability, a meaningful feature of ASD reflecting sensory, attentional, and cognitive differences.
methodsThis study investigates whether across-trial EEG variability enhances ASD classification compared to conventional mean EEG features. We hypothesize that capturing dynamic within-subject neural variability improves classification accuracy and offers deeper insights into ASD-related neural disruptions. We analyzed EEG power spectral features in individuals with and without ASD, extracting across-trial variability in five frequency bands alongside traditional mean EEG power metrics. Using machine learning, we compared classification performance and identified the most predictive neural markers.
resultsResults show that across-trial EEG variability outperformed mean EEG metrics, achieving 70.7% classification accuracy. Variability in delta and gamma bands is critical for distinguishing ASD, with robust cross-validation results and significant correlations with behavioral scores, supporting the clinical relevance and generalizability of neural variability as an ASD biomarker.
conclusionsBy incorporating neural variability into machine learning models, this study introduces a novel framework for improving biomarker-driven assessments. These findings highlight the potential for personalized tools that inform targeted interventions while offering insights into ASD neurophysiology. Future research should integrate longitudinal EEG analyses and multimodal neuroimaging to advance precision diagnostics in autism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.